Senior Scientific Director Novo Nordisk Virum, Hovedstaden, Denmark
Disclosure(s):
Rune Overgaard, PhD: No relevant disclosure to display
For semaglutide, we are close to completing 7 phase 3a programs in type 2 diabetes and obesity alone, with several additional pivotal trials for adjacent diseases and comorbidities- including semaglutide either as s.c. injections or tablets for oral administration, investigated as monotherapy or in combination with amylin or insulin analogues. This has provided a myriad of MIDD activities from treatment optimization, and portfolio decisions, to regulatory applications and informing healthcare professionals and patients. In this session we shall touch upon a few of these applications, to discuss how different modelling strategies can contribute and create value for MIDD applications throughout the value chain.
